menu
    • menu
    [{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Leo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Alfacalcidol","moa":"Vitamin D receptor","graph1":"Nephrology","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"12","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Divestment","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0.56000000000000005,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.56000000000000005,"dosageForm":"","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"12","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"12","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT-1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40000000000000002,"dosageForm":"Tablet","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"12","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Acquisition","leadProduct":"Gemcitabine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Cheplapharm Arzneimittel Gmbh"}]

    Find Clinical Drug Pipeline Developments & Deals by Cheplapharm Arzneimittel Gmbh

    Menu

    Cheplapharm Arzneimittel Gmbh

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cheplapharm Acquires Gemzar from Lilly

                            Details : CHEPLAPHARM acquires a proven chemotherapeutic agent, Gemzar (gemcitabine) from Lilly. It is indicated for the treatment of various types of cancer: non-small cell lung cancer, ovarian cancer etc.

                            Product Name : Gemzar

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : $825.9 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cheplapharm Places Notes in A Volume of €750m in Challenging Market Environment

                            Details : The proceeds from the new bonds will be used to finance the acquisition of the worldwide commercial rights for Zyprexa (olanzapine), an antipsychotic medication, from Eli Lilly and Company.

                            Product Name : Zyprexa

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 28, 2023

                            Lead Product(s) : Olanzapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : $825.9 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : AstraZeneca

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed

                            Details : AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapha...

                            Product Name : Atacand

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 04, 2021

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : AstraZeneca

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : AstraZeneca

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries

                            Details : AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.

                            Product Name : Atacand

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 30, 2020

                            Lead Product(s) : Candesartan Cilexetil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : AstraZeneca

                            Deal Size : $400.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $562.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

                            Details : The portfolio to be divested to Cheplapharm is comprised Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $562.0 million

                            September 08, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $562.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Cheplapharm Arzneimittel Gmbh

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alfacalcidol

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Recipient : Leo Pharma

                            Deal Size : $357.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Leo Pharma Sells Portfolio of Four Products to Cheplapharm

                            Details : The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.

                            Product Name : One-Alpha

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 31, 2020

                            Lead Product(s) : Alfacalcidol

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Recipient : Leo Pharma

                            Deal Size : $357.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth